Form 8-K · Current report
Keurig Dr Pepper 8-K, filed Aug 6, 2026
- Filed
- CIK
- 0001418135
- Accession no.
- 0001418135-26-000048
Summary
Keurig Dr Pepper reported second-quarter 2026 net sales of $7.31 billion, up 75.6% year over year, including the April 1 close of its JDE Peet's acquisition, with adjusted diluted EPS of $0.57, up 16.3%, and reaffirmed its full-year 2026 guidance. CEO Tim Cofer said Q2 EPS exceeded expectations and that the company remains on track for a separation of its beverage and coffee businesses in early 2027.
Key points
- Excluding JDE Peet's, legacy KDP net sales rose 7.3%, driven by 4.2% net price realization and 3.1% volume/mix growth.
- U.S. Refreshment Beverages net sales rose 10.0% to $2.9 billion, while U.S. Coffee net sales fell 3.2% to $918 million and JDE Peet's contributed $2.8 billion.
- 2026 guidance calls for net sales of $25.9–$26.4 billion and low-double-digit constant-currency adjusted diluted EPS growth, with a pro-forma management leverage ratio of about 4.1x at year-end.
- Second-quarter operating cash flow was $895 million and free cash flow was $714 million.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition. The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such a filing. On August 6, 2026, Keurig Dr Pepper Inc. (the "Company" or "KDP") issued a press release announcing the Company's financial results for the second quarter of 2026. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.